Eric J. F. Franssen

TL;DR: It is concluded that cyclosporin A can fully block the P‐gp function in the blood brain barrier and the testes and that PET enables the in vivo measurement of P‐glycoprotein function and reversal of its function non‐invasively.

TL;DR: Results obtained show the feasibility of using SPET and PET to study the functionality of MDR transporters in vivo and suggest that radiolabelled colchicine, verapamil and daunorubicin are feasible substrates with which to image Pgp function in tumours.

TL;DR: The results show the feasibility of in vivo P-gp function measurement under basal conditions and after modulation in solid tumors and in the brain, and PET and radiolabeled P-GP substrates may be useful as a clinical tool to select patients who might benefit from the addition of a P- gp modulator to MDR drugs.

TL;DR: It is concluded that LMWPs may indeed be of use as carriers for specific renal delivery of drugs, since renal cortex homogenates and lysosomal lysates are able to catabolize the protein and generate the parent drug from drug-LMWP conjugates bearing suitable spacers.

TL;DR: Positron emission tomography with the amino acid tracer L-[1-C-11]-tyrosine is a valid tracer for diagnosis of brain tumors and allowed quantification of PSR.